eTRANSAFE

enhancing TRANSLATIONAL SAFETY ASSESSMENT
through integrative knowledge management

Newsletter #2 - May 2019

Welcome

We are delighted to present the second issue of the eTRANSAFE newsletter!

The **eTRANSAFE** project will improve the efficiency of translational safety assessment

Keynote

By Hennicke Kamp, BASF

Member of the eTRANSAFE Scientific Advisory Board

As a member of the Scientific Advisory Board (SAB) of eTRANSAFE, I did have the pleasure to participate so far in two of the eTRANSAFE project meetings. In these, I saw a broad range of excellent scientists creating an optimal environment for a promising project. The collaborative use of pre-clinical and clinical data from the eTRANSAFE partners as well as public data bases are essential to develop ideas and tools for their application in the prediction of toxicity in relation to clinical effects. I personally like the idea and vision of eTRANSAFE and I believe that eTRANSAFE is an excellent model of pre-competitive collaboration between industry, academia and regulators for future improvement of human health.

However, our role in the SAB as critics of the project can be “unpleasant” to the eTRANSAFE partners. Besides myself, the SAB is composed of Paul Avillach (Harvard Medical School), Jose Castell (Hospital Universitario La Fe in Valencia), Michael Merz (Zurich University), and Jean-Marc Vidal (independent expert). From an outside perspective, we try to identify gaps between expectations and actual actions taken, we highlight missing opportunities, and we try to make sure that all relevant aspects are considered.

Often this means stating the obvious already known by all partners such as the lack of data submission, or delays in the fulfilment of the milestones which are key to the success of the project. By this we intend to demonstrate that also from an external perspective, important milestones need to be completed on time for the success of the project.

Beyond the acquired knowledge from the former eTOX IMI project, there are also other European or national projects working with and generating (pre-)clinical data for pharmaceuticals and other sectors of industry such as chemicals or food additives and ingredients (e.g., IMI TransBioLine, H2020 EU-ToxRisk). Such projects represent opportunities for strengthening the databases of eTRANSAFE and maybe for broadening the domain of applicability of the tools and models developed. By this, the results of eTRANSAFE will become highly attractive not only for other pharmaceutical companies, but also for other sectors of industry such as agrochemical or nutrition companies.

Hence, I will continue to work further with my colleagues from the SAB to encourage eTRANSAFE to make the planned progress and achieve results which are also attractive to partners like my home company, BASF. In this spirit, I am looking forward to the next meetings for discussing further challenges and build on the progress made so far by the consortium!

Sincerely,

Hennicke Kamp

Latest News

eTRANSAFE Research Reproducibility Workshop

eTRANSAFE is organising a Research Reproducibility Workshop next 4th of June 2019 in Barcelona. The aim of the workshop is to collect input from key stakeholders, including also risk assessors and regulators to establish a consortium-wide guideline proposal of data sharing for long-term sustainability, and model validation in the scope of eTRANSAFE.

Read more



eTRANSAFE at PhUSE CSS 2019

Two different posters will showcase the work being done in eTRANSAFE at the next PhUSE CSS, that will be held in Silver Spring, Maryland (US) from 9th to 11th June 2019.

“Analysis of clinical pathology parameters and histopathologic findings from eTOX”. Thomas R, Pinches M, Porter R, Camidge L. Partner: Lhasa
"Consolidating Study Outcomes in a Standardised, SEND-Compatible Structure". Drew P, Thomas R, Capella S. Partners: PDS, Lhasa, BSC

PHUSE Website

eTRANSAFE at SOT 2019

The eTRANSAFE project was represented by several partners (UL, MN-AM, UNIVIE and ROCHE) with four posters and an oral presentation in the framework of the Scientific Sessions.

Read more

Meet the Team

Interview with Annika Kreuchwig

Annika Kreuchwig is a researcher at BAYER AG, Pharmaceuticals. In this interview, she explains her involvement in the project to create a valuable platform in the drug development process...

Read more

Interview with Nicolas Bosc

Nicolas Bosc works as a researcher at ELIXIR-EMBL. In this interview, he explains his role within the project and the opportunity that the project brings to his career...

Read more

Upcoming events

eTRANSAFE 6th Consortium Meeting
5-6 June 2019 | Barcelona (ES)

European Workshop in Drug Design
19-24 May 2019 | Siena (IT)

PhUSE 2019 Computational Science Symposium
9-11 June 2019 | Maryland (US)

Eastern European Machine Learning Summer School
1-6 July 2019 | Bucharest (RO)

Computer Aided Drug Design
Gordon Research Conference
19-14 July 2019 | West Dover, VT (US)

Publications

In Silico models in drug development: where we are. Piñero J, Furlong L, Sanz F. *Curr Opin Pharmacol.* 2018. 42:111-121

Read more

www.etransafe.eu

Share Tweet Forward

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777365. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA.